Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK971086 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| placebo | DRUG | - |
| GSK971086 | DRUG | - |
Inclusion Criteria: * Males between 18 and 50 years of age (inclusive), at the time of signing the informed consent form. * Healthy, as determined by the Investigator, based on medical evaluations performed during the Screening Period including medical history, physical examination, clinical labora...
GSK971086 is an investigational small molecule developed by GSK plc for androgen deficiency. It is a Phase 1 clinical candidate in the endocrine therapeutic area. It has been studied in healthy adult male volunteers to assess safety, tolerability, and blood levels after single and repeat dosing.
GSK971086 is being developed for androgen deficiency, a condition characterized by low levels of male sex hormones. The clinical program has studied it in healthy adult males and in the context of androgen deficiency. It remains investigational and is not an approved treatment.
GSK971086 is developed by GSK plc, which trades under the ticker GSK. The company sponsored the Phase 1 clinical study of the compound in the United States. GSK plc is the sole developer named for this asset.
GSK971086 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The drug is investigational and has not been approved by the FDA for any indication.
GSK971086 has been evaluated in one completed Phase 1 trial, NCT00540553, titled a study to test safety, tolerability, and blood levels after one dose and seven days of dosing in healthy adult males. The trial enrolled 126 participants in the United States and was randomized and double blind.
GSK971086 is a small molecule being developed for androgen deficiency. It was studied in a Phase 1 trial measuring safety, tolerability, and blood levels after single and repeat dosing in healthy adult males. No molecular target is specified for this compound.